Stay updated with breaking news from Himara. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
IMARA Inc. (NASDAQ:IMRA – Get Rating) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totalling 121,300 shares, an increase of 55.9% from the March 15th total of 77,800 shares. Based on an average daily volume of 352,100 shares, the short-interest ratio is presently […]
SVB Leerink restated their market perform rating on shares of IMARA (NASDAQ:IMRA – Get Rating) in a research report report published on Wednesday morning, Marketbeat Ratings reports. SVB Leerink also issued estimates for IMARA’s Q1 2022 earnings at ($0.59) EPS, Q2 2022 earnings at ($0.57) EPS, Q3 2022 earnings at ($0.52) EPS, Q4 2022 earnings […]
IMARA (NASDAQ:IMRA – Get Rating) released its quarterly earnings data on Tuesday. The company reported ($0.53) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.75) by $0.22, Fidelity Earnings reports. During the same quarter in the previous year, the company earned ($1.09) EPS. Shares of IMRA stock traded up $0.14 during trading […]
Zacks Investment Research cut shares of IMARA (NASDAQ:IMRA – Get Rating) from a buy rating to a hold rating in a report issued on Tuesday morning, Zacks.com reports. According to Zacks, “Imara Inc. is a biopharmaceutical company. It engages in developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of […]